hmmm ... this is interesting... any mention at all in the recent conference call??? I guess Erck and Glenn don't know about this
"Isconova AB, a research and development company, develops and commercializes adjuvants and vaccines in Sweden. It provides its adjuvants for veterinary and human vaccines for an enhanced immune reaction with longer duration. The company’s products include Matrix-M that induces a cell-mediated and an antibody mediated immune response for use in vaccines for humans, dogs, and cats; Matrix-C for use in equine vaccines for horses; Matrix Q, which is used in research and development projects in cow and fish vaccines; and Matrix-F for use in vaccines for fishes. It also offers AbISCO research reagents, including AbISCO-100 for use in saponin sensitive animal species, such as mice. The company is headquartered in Uppsala, Sweden. Isconova AB is a subsidiary of Novavax, Inc. As of July 31, 2013, Isconova AB operates as a subsidiary of Novavax, Inc."